Consistent Pulmonary Drug Delivery with Whole Lung Deposition Using the Aerosphere Inhaler: A Review of the Evidence

References

• Global Initiative for Chronic Obstructive Lung Disease. 2020 report: global strategy for the diagnosis, management and prevention of COPD. 2020. Available from: https://goldcopd.org/gold-reports/. Accessed March 17, 2020.
   Google Scholar
• Global Initiative for Asthma. 2019 Report: global strategy for asthma management and prevention. 2019. Available from: https://ginasthma.org/. Accessed December 17, 2019.
   Google Scholar
• Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019;15(14):461–472. doi:10.2147/TCRM.S160365
   PubMedGoogle Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938. doi:10.1016/j.rmed.2011.01.005
   PubMed Web of Science ®Google Scholar
• Sanchis J, Gich I, Pedersen S. Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016;150(2):394–406. doi:10.1016/j.chest.2016.03.041
   PubMed Web of Science ®Google Scholar
• Lavorini F, Usmani OS. Correct inhalation technique is critical in achieving good asthma control. Prim Care Respir J. 2013;22(4):385–386. doi:10.4104/pcrj.2013.00097
   PubMedGoogle Scholar
• Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19(1):10. doi:10.1186/s12931-017-0710-y
   PubMed Web of Science ®Google Scholar
• Chrystyn H, van der Palen J, Sharma R, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017;27(1):22. doi:10.1038/s41533-017-0016-z
   PubMed Web of Science ®Google Scholar
• Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002;19(2):246–251. doi:10.1183/09031936.02.00218402
   PubMed Web of Science ®Google Scholar
• Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497–1504. doi:10.1164/rccm.200410-1414OC
   PubMed Web of Science ®Google Scholar
• Van Holsbeke C, De Backer J, Vos W, Marshall J. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler. Ther Adv Respir Dis. 2018;12:1753466618760948. doi:10.1177/1753466618760948
   Web of Science ®Google Scholar
• Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv. 2012;25(3):140–147. doi:10.1089/jamp.2011.0916
   PubMed Web of Science ®Google Scholar
• Verbanck S, Biddiscombe MF, Usmani OS. Inhaled aerosol dose distribution between proximal bronchi and lung periphery. Eur J Pharm Biopharmaceutics. 2020;152:18–22. doi:10.1016/j.ejpb.2020.04.019
   PubMed Web of Science ®Google Scholar
• Ding B, Kallenbach L, Slipski L, Wilk A, O’Brien D, Guranlioglu D. Demographics and clinical characteristics of patients with COPD utilizing LAMA/LABA fixed-dose combination therapy: a U.S. database study. Thorax. 2018;73(Suppl 4):A233–A233. doi:10.1136/thorax-2018-212555.399
   Web of Science ®Google Scholar
• Stein SW, Sheth P, Hodson PD, Myrdal PB. Advances in metered dose inhaler technology: hardware development. AAPS PharmSciTech. 2014;15(2):326–338. doi:10.1208/s12249-013-0062-y
   PubMed Web of Science ®Google Scholar
• Newman SP. Principles of metered-dose inhaler design. Respir Care. 2005;50(9):1177–1190.
   PubMedGoogle Scholar
• Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech. 2014;15(2):434–455. doi:10.1208/s12249-013-0063-x
   PubMed Web of Science ®Google Scholar
• Lechuga-Ballesteros D, Noga B, Vehring R, Cummings RH, Dwivedi SK. Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. Future Med Chem. 2011;3(13):1703–1718. doi:10.4155/fmc.11.133
   PubMed Web of Science ®Google Scholar
• Michael Y, Snowden MJ, Chowdhry BZ, Ashurst IC, Davies-Cutting CJ, Riley T. Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system. Int J Pharm. 2001;19(221(1–2)):165–174. doi:10.1016/S0378-5173(01)00678-0
   Web of Science ®Google Scholar
• Vehring R, Lechuga-Ballesteros D, Joshi V, Noga B, Dwivedi SK. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28(42):15015–15023. doi:10.1021/la302281n
   PubMed Web of Science ®Google Scholar
• Wauthoz N, Amighi K. Phospholipids in pulmonary drug delivery. Eur J Lipid Sci Technol. 2014;116(9):1114–1128. doi:10.1002/ejlt.201300368
   Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals LP. Bevespi Aerosphere™ Prescribing Information. 2019. Available from: http://www.azpicentral.com/bevespi/bevespi_pi.pdf. Accessed July 2, 2019.
   Google Scholar
• AstraZeneca Pharmaceuticals LP. Breztri Aerosphere™ Prescribing Information. 2020. Available from: https://www.azpicentral.com/breztri/breztri.pdf. Accessed November 13, 2020.
   Google Scholar
• AstraZeneca AB. Bevespi Aerosphere summary of product characteristics. 2018. Available from: https://www.ema.europa.eu/en/documents/product-information/bevespi-aerosphere-epar-product-information_en.pdf. Accessed June 13, 2019.
   Google Scholar
• European Medicines Agency. CHMP summary of positive opinion for Trixeo Aerosphere. 2020. Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trixeo-aerosphere_en.pdf. Accessed November 13, 2020.
   Google Scholar
• AstraZeneca. Bevespi Aerosphere approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease. 2019. Available from: https://www.astrazeneca.com/media-centre/press-releases/2019/bevespi-aerosphere-approved-by-the-japanese-ministry-of-health-labour-and-welfare-for-patients-with-chronic-obstructive-pulmonary-disease-19062019.html. Accessed 2 July 2019.
   Google Scholar
• AstraZeneca. Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease. 2019. Available from: https://www.astrazeneca.com/media-centre/press-releases/2019/breztri-aerosphere-pt010-approved-in-japan-for-patients-with-chronic-obstructive-pulmonary-disease-19062019.html. Accessed July 2, 2019.
   Google Scholar
• AstraZeneca. Bevespi Aerosphere approved in China for patients with COPD. 2020. Available from: https://www.astrazeneca.com/media-centre/press-releases/2020/bevespi-aerosphere-approved-in-china-for-patients-with-copd.html. Accessed July 7, 2020.
   Google Scholar
• AstraZeneca. AstraZeneca’s triple-combination therapy approved in China for patients with COPD. 2019. Available from: https://www.astrazeneca.com/media-centre/press-releases/2019/astrazenecas-triple-combination-therapy-approved-in-china-for-patients-with-copd-23122019.html. Accessed December 23, 2019.
   Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017;151(2):340–357. doi:10.1016/j.chest.2016.11.028
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Collier DJ, Gon Y, et al. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized phase III study conducted in Asia, Europe, and the USA. Int J Chron Obstruct Pulmon Dis. 2018;13:2969–2984. doi:10.2147/COPD.S171835
   PubMed Web of Science ®Google Scholar
• Hanania NA, Tashkin DP, Kerwin EM, et al. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017;126:105–115. doi:10.1016/j.rmed.2017.03.015
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-8
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Fabbri LM, Ferguson GT, et al. Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD. Chest. 2017;152(6):1169–1178. doi:10.1016/j.chest.2017.07.007
   PubMed Web of Science ®Google Scholar
• Doty A, Schroeder J, Vang K, et al. Drug delivery from an innovative LAMA/LABA co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliability. AAPS PharmSciTech. 2018;19(2):837–844. doi:10.1208/s12249-017-0891-1
   PubMed Web of Science ®Google Scholar
• Sheth P, Archbell J, Miller K, Wu L, Vang K, Mack P. Drug delivery from a novel fixed-dose ICS/LAMA/LABA MDI using co-suspension delivery technology: evidence of consistency, robustness, and reliability. Poster presented at: American Association of Pharmaceutical Scientists Pharmsci 360; 4 November 2019; San Antonio, Texas, USA. Available from: https://shwca.se/pharmsci2019. Accessed January 7, 2021.
   Google Scholar
• Hamilton M, Leggett R, Pang C, Charles S, Gillett B, Prime D. In vitro dosing performance of the ELLIPTA® dry powder inhaler using asthma and COPD patient inhalation profiles replicated with the electronic lung (eLung). J Aerosol Med Pulm Drug Deliv. 2015;28(6):498–506. doi:10.1089/jamp.2015.1225
   PubMed Web of Science ®Google Scholar
• De Maria R, Zagnoni I, Bodria A, et al. Foster®: a high-efficiency combination metered dose inhaler with consistent particle size distribution at alternative flow rates. Combination Prod Ther. 2014;4(1):1–5. doi:10.1007/s13556-013-0006-6
   Google Scholar
• Johal B, Howald M, Fischer M, Marshall J, Venthoye G. Fine particle profile of fluticasone propionate/formoterol fumarate versus other combination products: the DIFFUSE study. Combination Prod Ther. 2013;3(1):39–51. doi:10.1007/s13556-013-0003-9
   Google Scholar
• Wu L, Van Holsbeke C, Mack P. Consistent lung delivery of inhaled triple ICS/LAMA/LABA combination using the co-suspension delivery technology: an in silico modelling study. Poster presented at: American Association of Pharmaceutical Scientists Pharmsci 360; 5 November 2019; San Antonio, Texas, USA. Available from: https://shwca.se/pharmsci2019. Accessed January 7, 2021.
   Google Scholar
• Hatley RH, Parker J, Pritchard JN, von Hollen D. Variability in delivered dose from pressurized metered-dose inhaler formulations due to a delay between shake and fire. J Aerosol Med Pulm Drug Deliv. 2017;30(1):71–79. doi:10.1089/jamp.2015.1284
   PubMed Web of Science ®Google Scholar
• Thorsson L, Edsbäcker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur Respir J. 1998;12(6):1340–1345. doi:10.1183/09031936.98.12061340
   PubMed Web of Science ®Google Scholar
• Chrystyn H. Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol. 2001;51(4):289–299. doi:10.1046/j.1365-2125.2001.01304.x
   PubMed Web of Science ®Google Scholar
• Vos W, de Backer J, Schroeder J, Sommerville M, Dwivedi S, De Backer W. In-silico assessment of airway deposition using functional respiratory imaging for mono, dual and triple combination co-suspension metered dose inhaler formulations. Am J Respir Crit Care Med. 2016;193:A5811.
   Web of Science ®Google Scholar
• Hajian B, De Backer J, Vos W, Van Holsbeke C, Clukers J, De Backer W. Functional respiratory imaging (FRI) for optimizing therapy development and patient care. Expert Rev Respir Med. 2016;10(2):193–206. doi:10.1586/17476348.2016.1136216
   PubMed Web of Science ®Google Scholar
• Taylor G, Warren S, Dwivedi S, et al. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology. Eur J Pharm Sci. 2018;111:450–457. doi:10.1016/j.ejps.2017.10.026
   PubMed Web of Science ®Google Scholar
• Israel S, Kumar A, DeAngelis K, et al. Pulmonary deposition of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects. Eur J Pharm Sci. 2020;2020(153):105472.
   Web of Science ®Google Scholar
• Darquenne C, Fleming JS, Katz I, et al. Bridging the gap between science and clinical efficacy: physiology, imaging, and modeling of aerosols in the lung. J Aerosol Med Pulm Drug Deliv. 2016;29(2):107–126. doi:10.1089/jamp.2015.1270
   PubMed Web of Science ®Google Scholar
• Chrystyn H. Methods to determine lung distribution of inhaled drugs - could gamma scintigraphy be the gold standard? Br J Clin Pharmacol. 2000;49(6):525–528. doi:10.1046/j.1365-2125.2000.00215.x
   PubMed Web of Science ®Google Scholar
• Newman S, Bennett WD, Biddiscombe M, et al. Standardization of techniques for using planar (2D) imaging for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv. 2012;25(Suppl. 1):S10–S28. doi:10.1089/jamp.2012.1Su4
   PubMedGoogle Scholar
• Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3(4):763–770. doi:10.2147/COPD.S3930
   PubMedGoogle Scholar
• De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23(3):137–148. doi:10.1089/jamp.2009.0772
   PubMed Web of Science ®Google Scholar
• Hirst PH, Pitcairn GR, Weers JG, et al. In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm Res. 2002;19(3):258–264. doi:10.1023/A:1014482615914
   PubMed Web of Science ®Google Scholar
• Leach CL, Kuehl PJ, Chand R, McDonald JD. Respiratory tract deposition of HFA-beclomethasone and HFA-fluticasone in asthmatic patients. J Aerosol Med Pulm Drug Deliv. 2016;29(2):127–133. doi:10.1089/jamp.2014.1199
   PubMed Web of Science ®Google Scholar
• Leach CL, Kuehl PJ, Chand R, Ketai L, Norenberg JP, McDonald JD. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol. 2012;108(3):195–200. doi:10.1016/j.anai.2012.01.010
   PubMed Web of Science ®Google Scholar
• De Backer W, De Backer J, Vos W, et al. A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2673–2684. doi:10.2147/COPD.S171707
   PubMed Web of Science ®Google Scholar
• Rabe KF. GFF MDI for the improvement of lung function in COPD – a look at the PINNACLE-1 and PINNACLE-2 data and beyond. Expert Rev Clin Pharm. 2017;10(7):685–698. doi:10.1080/17512433.2017.13202180
   PubMed Web of Science ®Google Scholar
• De Backer J, Vos W, Vinchurkar S, et al. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging. J Aerosol Med Pulm Drug Deliv. 2015;28(2):88–99. doi:10.1089/jamp.2013.1064
   PubMed Web of Science ®Google Scholar
• De Backer LA, Vos W, De Backer J, Van Holsbeke C, Vinchurkar S, De Backer W. The acute effect of budesonide/formoterol in COPD: a multi-slice computed tomography and lung function study. Eur Respir J. 2012;40(2):298–305. doi:10.1183/09031936.00072511
   PubMed Web of Science ®Google Scholar
• De Backer LA, Vos WG, Salgado R, et al. Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:637–646. doi:10.2147/COPD.S21917
   PubMed Web of Science ®Google Scholar
• DeBacker W, DeBacker J, Verlinden I, et al. Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD. Ther Adv Respir Dis. 2020;14:1–13. doi:10.1177/1753466620916990
   Web of Science ®Google Scholar
• Usmani OS, Capstick T, Chowhan H, Scullion J Choosing an appropriate inhaler device for the treatment of adults with asthma or COPD. 2017. Available from: https://www.guidelines.co.uk/respiratory/inhaler-choice-guideline/252870.article. Accessed November 19, 2018.
   Google Scholar
• Price D, Chrystyn H, Kaplan A, et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res. 2012;4(4):184–191. doi:10.4168/aair.2012.4.4.184
   PubMed Web of Science ®Google Scholar
• Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis. 2016;12:59–71. doi:10.2147/COPD.S117196
   PubMed Web of Science ®Google Scholar
• Lavorini F, Fontana GA. Targeting drugs to the airways: the role of spacer devices. Expert Opin Drug Deliv. 2009;6(1):91–102. doi:10.1517/17425240802637862
   PubMed Web of Science ®Google Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–1107. doi:10.1513/AnnalsATS.201702-156PS
   PubMed Web of Science ®Google Scholar
• Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83. doi:10.1183/09031936.00024807
   PubMed Web of Science ®Google Scholar
• Hakim A, Khan Y, Esteban I, et al. Low-dose budesonide/formoterol counteracts airway inflammation and improves lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019;199(5):662–664. doi:10.1164/rccm.201808-1590LE
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Hess DR. Aerosol delivery devices for obstructive lung diseases. Respir Care. 2018;63(6):708–733. doi:10.4187/respcare.06290
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study to evaluate the effects of BGF and GFF on specific image based airway volumes and resistance in subjects with moderate to severe COPD. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03836677. Accessed May 22, 2019.
   Google Scholar
• ClinicalTrials.gov. A scintigraphy study of PT010 in COPD patients (RD708/34000). 2019. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03906045. Accessed May 22, 2019.
   Google Scholar
• Vincken W, Levy ML, Scullion J, Usmani OS, Dekhuijzen PNR, Corrigan CJ. Spacer devices for inhaled therapy: why use them, and how? ERJ Open Res. 2018;4(2):00065–02018. doi:10.1183/23120541.00065-2018
   PubMedGoogle Scholar
• ClinicalTrials.gov. A study to assess the efficacy and safety of budesonide/albuterol metered-dose inhaler (BDA MDI/PT027) in adults and children 4 years of age or older with asthma (MANDALA). 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03769090. Accessed May 21, 2019.
   Google Scholar
• ClinicalTrials.gov. A study to assess the efficacy and safety of budesonide/albuterol metered-dose inhaler (BDA MDI/PT027) used 4 times daily in adults and children 4 years of age or older with asthma (DENALI). 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03847896. Accessed May 21, 2019.
   Google Scholar
• Battisti WP, Wager E, Baltzer L, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461–464. doi:10.7326/M15-0288
   PubMed Web of Science ®Google Scholar